NCT07431281 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07431281
Title	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	gastric adenocarcinoma gastroesophageal junction adenocarcinoma esophagus adenocarcinoma
Therapies	AZD0901 + Capecitabine + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab AZD0901 + AZD2936 + Capecitabine AZD0901 + Capecitabine Capecitabine + Oxaliplatin + Zolbetuximab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS

Additional content available in CKB BOOST